According to a story in the Huffington Post, federal officials are warning of an “alarming” increase in diabetes rates, projecting that as many as one in three U.S. adults could have the condition by 2050 if current trends continue.
The U.S. Centers for Disease Control and Prevention already estimate that one in 10 Americans – about 24 million people — now have diabetes. According to the new estimate, that number may rise to 76 million to 100 million in the coming ...
continue reading...
Shares of pharmaceutical companies that make newer types of diabetes medication have fallen, following the U.S. Food and Drug Administration’s announcement that the agency is looking into potential health risks, according to a March 14 story in Bloomberg.
Among those drugs are Merck’s Januvia and Bristol-Myers Squibb’s Byetta.
The U.S. Food and Drug Administration has said the agency is seeking more information about recent findings linking the drugs to an increased risk ...
continue reading...
Reuters reports that GlaxoSmithKline, Britain’s largest pharmaceutical manufacturer, has filed for approval of a diabetes drug called albiglutide in both the United States and Europe.
The story says albiglutide is among a class of medicines that increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.
A recent study found two other diabetes drugs in that class, Merck’s Januvia and Bristol-Myers Squibb’s Byetta, may double the risk of a ...
continue reading...The author of a study that found two diabetes drugs may double the risk of a dangerous pancreas inflammation says his findings show a need for more research into the subject.
Bloomberg has reported on the study, which found that Merck’s diabetes drug Januvia and Bristol-Myers Squibb’s Byetta may double a user’s risk of pancreatitis.
The story says both drugs increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.
Bloomberg quotes Sonal Singh, an assistant professor of medicine at ...
continue reading...A blog entry on Consumer Reports recommends that patients taking the diabetes medications Byetta or Januvia ask their doctors about possibly taking other medications.
According to Consumer Reports, people taking those two drugs may have a small but increased risk for a condition marked by stomach pain and nausea. More troubling, a new study in JAMA Internal Medicine links both drugs with an increased risk of an inflamed pancreas, called pancreatitis. The researchers noted that pancreatitis is a risk factor for ...
continue reading...A new analysis of insurance records published in the journal JAMA Internal Medicine adds to growing evidence of a connection between two popular diabetes drugs and a potentially deadly inflammation of the pancreas.
According to a report on the study in Bloomberg, patients hospitalized with pancreatitis — linked to cancer and kidney failure — were twice as likely to be taking Merck’s Januvia or Bristol-Myers’s Byetta than a control group of ...
continue reading...
